ATE231511T1 - Magnesium(-)hydroxycitrat, verfahren zur herstellung, anwendung und pharmazeutische zusammensetzungen, die sie enthalten - Google Patents

Magnesium(-)hydroxycitrat, verfahren zur herstellung, anwendung und pharmazeutische zusammensetzungen, die sie enthalten

Info

Publication number
ATE231511T1
ATE231511T1 AT97911285T AT97911285T ATE231511T1 AT E231511 T1 ATE231511 T1 AT E231511T1 AT 97911285 T AT97911285 T AT 97911285T AT 97911285 T AT97911285 T AT 97911285T AT E231511 T1 ATE231511 T1 AT E231511T1
Authority
AT
Austria
Prior art keywords
hydroxycitrate
magnesium
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT97911285T
Other languages
English (en)
Inventor
Ravi Shrivastava
Patrick Lambropoulos
Original Assignee
Ravi Shrivastava
Patrick Lambropoulos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ravi Shrivastava, Patrick Lambropoulos filed Critical Ravi Shrivastava
Application granted granted Critical
Publication of ATE231511T1 publication Critical patent/ATE231511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02—Magnesium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97911285T 1996-10-22 1997-10-17 Magnesium(-)hydroxycitrat, verfahren zur herstellung, anwendung und pharmazeutische zusammensetzungen, die sie enthalten ATE231511T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9613094A FR2754820B1 (fr) 1996-10-22 1996-10-22 Le (-)hydroxycitrate de magnesium, procede de preparation, applications, et compositions notamment pharmaceutiques le renfermant
PCT/FR1997/001860 WO1998017671A1 (fr) 1996-10-22 1997-10-17 Le (-)hydroxycitrate de magnesium, procede de preparation, applications, et compositions notamment pharmaceutiques le renfermant

Publications (1)

Publication Number Publication Date
ATE231511T1 true ATE231511T1 (de) 2003-02-15

Family

ID=9497072

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97911285T ATE231511T1 (de) 1996-10-22 1997-10-17 Magnesium(-)hydroxycitrat, verfahren zur herstellung, anwendung und pharmazeutische zusammensetzungen, die sie enthalten

Country Status (11)

Country Link
US (1) US6221901B1 (de)
EP (1) EP0937085B1 (de)
JP (1) JP2001503744A (de)
KR (1) KR20000052687A (de)
AT (1) ATE231511T1 (de)
AU (1) AU717533B2 (de)
CA (1) CA2268876A1 (de)
DE (1) DE69718662T2 (de)
ES (1) ES2191174T3 (de)
FR (1) FR2754820B1 (de)
WO (1) WO1998017671A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733418B1 (fr) * 1995-04-28 1997-08-01 Ravi Shrivastava Nouvelles associations comprenant du (-) hydroxycitrate et presentant notamment de nouvelles activites therapeutiques
US6160172A (en) * 1997-08-27 2000-12-12 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties
US6503905B1 (en) * 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
US7015250B2 (en) * 2000-02-09 2006-03-21 Glykon Technologies Group, Llc Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid
US6476071B1 (en) * 2001-05-07 2002-11-05 Dallas L. Clouatre Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
US6482858B1 (en) 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
US6441041B1 (en) 2001-06-20 2002-08-27 Dallas L. Clouatre (-)-hydroxycitric acid for the prevention of osteoporosis
US20030187055A1 (en) * 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
FR2838645B1 (fr) * 2002-04-19 2004-05-28 Ravi Shrivastava Nouvelles compositions synergiques de vitamines, de mineraux et d'oligo-elements pour stimuler l'elimination des lipides intracellulaires
US7507421B2 (en) * 2002-04-30 2009-03-24 Unibar Corporation Hydroxycitric acid salt composition and method of making
US8394856B2 (en) * 2002-07-02 2013-03-12 Glykon Technologies Group, Llc (-)-Hydroxycitric acid for controlling inflammation
US20040049624A1 (en) * 2002-09-06 2004-03-11 Oak Technology, Inc. Network to computer internal interface
US7189416B2 (en) * 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP3655292B2 (ja) * 2003-04-14 2005-06-02 株式会社日立製作所 粒子線照射装置及び荷電粒子ビーム照射装置の調整方法
AU2003241151A1 (en) 2003-05-19 2004-12-03 Indfrag Limited A novel composition of complex metal salt of garcinia acid, a process for preparing the same and use thereof
WO2004105733A1 (en) * 2003-05-29 2004-12-09 Glykon Technologies Group, Llc Method and composition for stable and controlled delivery of (-)-hydroxycitric acid
US7261769B2 (en) * 2003-07-03 2007-08-28 Unibar Corporation Stabilized anthocyanin extract from Garcinia indica
US20050009919A1 (en) * 2003-07-07 2005-01-13 Clouatre Dallas L. Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
CA2538929A1 (en) * 2003-09-11 2005-03-24 Glykon Technologies Group, Llc Enteric delivery of (-)-hydroxycitric acid
KR101100904B1 (ko) * 2003-10-22 2012-01-02 라비 슈리바스타바 세포내 지질 부착물 제거를 자극하는 비타민, 미네랄 및미량원소로 이루어진 새로운 상승작용성 조성물
WO2005085164A1 (en) * 2004-03-09 2005-09-15 Ganga Raju Gokaraju Novel triple mineral salts of (-)-hydroxycitric acid and processes for preparing the same
CA2579197C (en) * 2004-04-19 2012-12-11 Laila Impex New double salts of (-)-hydroxycitric acid and a process for preparing the same
US20050276839A1 (en) * 2004-06-10 2005-12-15 Rifkin Calman H Appetite satiation and hydration beverage
US20060025482A1 (en) * 2004-07-29 2006-02-02 Clouatre Dallas L (-)-Hydroxycitric acid for the modulation of angiotensin-converting enzyme
US20060025483A1 (en) * 2004-07-29 2006-02-02 Clouatre Dallas L (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification
US20060153934A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and magnesium
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
CN109394819A (zh) * 2018-09-14 2019-03-01 中国药科大学 藤黄中一种黄酮类化合物的医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3671583A (en) * 1968-03-25 1972-06-20 Sandoz Ag Glutaric acid derivatives
FR2716374B1 (fr) * 1994-02-18 1996-04-19 Sederma Sa Nouvelles compositions cosmétiques ou dermopharmaceutiques contenant des extraits de plantes.
US5536516A (en) * 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
FR2733418B1 (fr) * 1995-04-28 1997-08-01 Ravi Shrivastava Nouvelles associations comprenant du (-) hydroxycitrate et presentant notamment de nouvelles activites therapeutiques
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats

Also Published As

Publication number Publication date
EP0937085A1 (de) 1999-08-25
ES2191174T3 (es) 2003-09-01
FR2754820A1 (fr) 1998-04-24
FR2754820B1 (fr) 1999-10-22
KR20000052687A (ko) 2000-08-25
CA2268876A1 (fr) 1998-04-30
AU717533B2 (en) 2000-03-30
US6221901B1 (en) 2001-04-24
DE69718662T2 (de) 2003-10-09
WO1998017671A1 (fr) 1998-04-30
DE69718662D1 (de) 2003-02-27
JP2001503744A (ja) 2001-03-21
AU4871797A (en) 1998-05-15
EP0937085B1 (de) 2003-01-22

Similar Documents

Publication Publication Date Title
ATE231511T1 (de) Magnesium(-)hydroxycitrat, verfahren zur herstellung, anwendung und pharmazeutische zusammensetzungen, die sie enthalten
NO20002788D0 (no) Nye forbindelser
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
DE69720787D1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
ATE232543T1 (de) 11beta-halogen-7alpha-substituierte-estratriene verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha- substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
WO2005034889A3 (en) Method for imparting artificial tan to human skin
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
ES2062145T3 (es) 1,8-naftiridinas substituidas.
FI953173A0 (fi) Orto-aminosubstituoituja bentsolyyliguanidiinejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
DE69711633D1 (de) Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
EP0747351A3 (de) Thiokationische Lipide, pharmazeutische Zusammensetzungen und ihre Anwendungsmethoden
DE69528302D1 (de) Verfahren zur Herstellung von Glutaminreiche Peptiden und Nahrungsmittelzusammensetzungen die diese Peptide enthalten
AU3255295A (en) Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
DE69810906D1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
DE4493859D2 (de) Estriol enthaltendes hormonales Mittel zur Prophylaxe und Behandlung arterieller Erkrankungen beim Mann, Verfahren zu seiner Herstellung und dessen Verwendung
DE69514293T2 (de) Verfahren zur Herstellung von parfumierter Zusammensetzungen und Produkten; die so herstellen Produkte
DE69918339D1 (de) Pharmazeutische zusammensetzungen die selegilin und ginkgo biloba extrakt enthalten zur behandlung von demenz
GEU1998374Y (en) Method for Receiving Means for Treatment of Cardiovascular Diseases
DE60210268D1 (de) Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten
IL135416A0 (en) The use of an aminotetralin derivative in the preparation of pharmaceutical compositions for the treatment of cardiovascular diseases
DE9419557U1 (de) Vorrichtung zur partiellen Behandlung von Oberflächen, insbesondere zur medizinischen Behandlung von Körperteilen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties